LDL-C goal Attainment Among Patients Newly Diagnosed With Coronary Heart Disease or Diabetes in a Commercial HMO

ReseaRch ditionalmonth),and (e) monthssupply of lipid-modifying medication (or = 1.04, 95% ci, 1.01-1.07 per additionalmonth),and were lower for LdL-c ≥ 130 mg per dL in months1-6 (or = 0.53, 95% ci, 0.35-0.82) and a histor y of dyslipidemia (or = 0.54, 95% ci, 0.35-0.83). the odds of LdL-c goal attainment were not affectedby diagnosis(chd vs. diabetes),gender , statin titr ation(34% of patients), lipid-modifying drug switc hing (39% of patients), or tr eatment with a high-potenc y LdL-c-lo wering drug dosage (one of sufficientstr engthto reduce LdL-c by > 40%). concLusion: of patients receiving lipid testing and lipid drug tr eatment in the 6 monthsafteran initialdiagnosisof chd or diabetes,61% were not at the LdL-c goal of < 100 mg per dL. among thosenot atLdL-c goal in the first 6 monthsof tr eatment, only abouthalf who continuedtr eatment subsequently attained their LdL-c goal, despitestatin titr ationor switc hing of their lipid- modifying drug ther apy.